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Abstract
Acute myeloid leukemia (AML) is associated with the sequential accumulation of acquired
genetic alterations. Although at diagnosis cytogenetic alterations are frequent in AML,
roughly 50% of patients present an apparently normal karyotype (NK), leading to a highly
heterogeneous prognosis. Due to this significant heterogeneity, it has been suggested that
different molecular mechanisms may trigger the disease with diverse prognostic implica-
tions. We performed whole-exome sequencing (WES) of tumor-normal matched samples of
de novo AML-NK patients lacking mutations in NPM1, CEBPA or FLT3-ITD to identify new
gene mutations with potential prognostic and therapeutic relevance to patients with AML.
Novel candidate-genes, together with others previously described, were targeted rese-
quenced in an independent cohort of 100 de novo AML patients classified in the cytogenetic
intermediate-risk (IR) category. A mean of 4.89 mutations per sample were detected in 73
genes, 35 of which were mutated in more than one patient. After a network enrichment anal-
ysis, we defined a single in silico model and established a set of seed-genes that may trigger
leukemogenesis in patients with normal karyotype. The high heterogeneity of gene muta-
tions observed in AML patients suggested that a specific alteration could not be as essential
as the interaction of deregulated pathways.
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Introduction
Acute myeloid leukemia (AML) is associated with the sequential accumulation of acquired
genetic alterations and epigenetic changes in hematopoietic stem cells that alter processes
involved in proliferation, differentiation and self-renewal. At diagnosis, cytogenetic alterations
are frequent in AML patients [1,2]. Nevertheless, at least 50% of patients present an apparently
normal karyotype (NK) being its prognosis highly heterogeneous. These patients are conse-
quently classified in the cytogenetic intermediate-risk (IR) category. However, their significant
heterogeneity suggests that there are different molecular mechanisms involved in the develop-
ment of the disease as well as related to different prognostic implications [3–5]. The recent
progress of next-generation sequencing (NGS) technologies has allowed for the identification
of a growing number of novel mutations in leukaemias [6–9]. Their application has led to
broaden the list of genes that seems to be involved in the pathogenesis of such disorders.
Consequently, it has reflected their complexity and described patterns of cooperation and
exclusion between different genes and cellular pathways involved in the mechanisms of leuce-
mogenesis. In recent years, The Cancer Genome Atlas (TCGA) has collected data from exomic
or genomic sequencing, expression, methylation, and genotyping of 200 adult patients with
AML, identifying 23 different frequently mutated genes [10]. These genes were grouped into 8
different categories by their cellular function, detecting at least one mutation per group in 99%
of the studied AML patients. Recently, Papaemmanuil et al. defined 3 additional molecular
subgroups in AML patients with prognostic implications [11]. However, clinicians only rely
on the presence of alterations of 3 well established molecular markers, NPM1, CEBPA or
FLT3-ITD, for the diagnosis classification of patients with AML-IR [12].
To extend our knowledge on subtle genetic alterations involved in AML-NK, in this study,
we have performed whole-exome sequencing (WES) of tumor-normal matched samples on a
selected discovery cohort of de novo AML patients. To this aim, we studied samples of leuke-
mia cells from adults under the age of 60 years who lacked cytogenetic abnormalities and well
known molecular features that is, wild-type NPM1, CEBPA, and FLT3–ITD. Genes identified
from this analysis were validated on an independent cohort by targeted resequencing. Finally,
network analysis [13] was performed in silico to assess their putative role as driver genes.
Material and methods summary
We performed whole-exome sequencing (WES) of tumor-normal matched samples from 7 de
novoAML-NK patients without mutations inNPM1,CEBPA and FLT3–ITD (“discovery cohort”).
WES data were analyzed using an in-house bioinformatics pipeline [14] to compare the coding
sequence of matched samples, filter out germline variants and identify somatically acquired delete-
rious changes. The variants detected were confirmed in both samples of each patient by targeted
sequencing using an Ion AmpliSeq™ analysed in an Ion Proton™ System. By using the SureDesign
Tool (Agilent) for NGS we developed a custom design targeting hotspot regions of 55 genes found
mutated in the discovery cohort. Furthermore, complete coding sequence of extra 32 genes
(reported to be mutated in at least 2% of patients from previous AML studies [10]) were also
included. This design was tested in 100 additional de novoAML-IR patients (“validation cohort”).
Variants were selected according to VAF1%, its absence in the healthy population (UCSC Com-
mon SNPs; MAF< 0.01) and its putative effect on the protein (excluding synonymous mutations).
Finally, network enrichment analysis [13–16] was used to assess the candidate genes on the basis of
their connectivity, mutational recurrence and co-occurrence and cancer related functionalities.
This study was approved by the Research Ethics Board of IISLAFE (No.2012/0175) and
informed consent in accordance with the Declaration of Helsinki was obtained before taking
sample for genetic and genomic research.
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Results
Whole exome sequencing
We characterized a discovery cohort of 7 AML-NK de novo patients from whom paired diag-
nosis and complete remission DNA samples were available. Clinical characteristics of the
patients at diagnosis are summarized in S1 Table. The target coverage average in both diagnos-
tic and remission samples and the mean of reads by genomes was 228.97(±125.78)x and 32944
(±4192), respectively (S2 and S3 Tables). A total of 402,412 variant positions were detected in
all sequenced exons from all the samples. After an accurate filtering of the sequencing data
[14], a total of 102 candidate somatic variants (94 missense SNVs and 8 small indels) were
found (S3 Table). The distribution of the number of variants per exome showed an average of
30 mutations per sample (range 22–37). Recurrent mutations or common mutated genes were
not observed within the seven cases. Targeted resequencing of both samples of the discovery
cohort confirmed 64/102 deleterious somatic variants in 55 genes. Among them, 57 were mis-
sense mutations and 8 indels, which stood for an average of 9.2 mutations by sample (range
3–22). Of these 55 candidate genes, 26 were previously reported as mutated in AML patients
in previous studies [10, 11]. Detailed information is provided at S3 Table.
Frequency and distribution of 87 genes in a validation cohort of AML
patients
We further examined the mutation frequency of our candidate genes in an independent vali-
dation cohort of 100 de novo AML patients with intermediate cytogenetic risk. Details of the
validation cohort are provided in S4 Table. Overall, mean target coverage was 260±106x, with
an absolute median coverage of 220x at positions where mutations were identified. After pro-
cessing the raw sequencing data with the procedures described in [14] we identified a total of
158 high-confidence different variants. Mutations were predominantly missense substitutions
(53%), frameshift indels (34%), and nonframeshift indels (6%), in splice site regions (4%), non-
senses (2%), or ncRNA (1%) (S5 Table). A mean of 4.89 mutations per sample (range 0–10)
were detected. Variants were detected affecting 73 different genes, being 28 of these variants
concurrently harboured in more than one patient. Among the mutated genes, 35 showed
mutations in at least 7% of the patients (range 7–34%), being the most frequent mutated genes
NPM1,DNMT3A, FLT3, TET2 and ASXL1 (S5 Table). In silico analysis showed that most of
the observed mutations were reported in the COSMIC database as mutations implicated in
cancer. In addition, as we expected, recurrent hotspots previously reported were detected in
genes such as DNMT3A,NPM1,NRAS, KRAS, FLT3, IDH2 and IDH1 (S5 Table). Finally, we
analysed the co-occurrence of the identified mutations in our validation cohort, and identified
that patients with DNMT3A,NPM1 and FLT3 did not usually harboured other mutations. In
contrast, patients with DNMT3A and NPM1 appeared simultaneously with genes such as
IDH2, PTPN11 or RUNX1. Finally, patients lacking mutations in DNMT3A showed a pattern
that included a miscellany of altered genes (Fig 1).
We found somatic mutations with deleterious effect in 100% of patients of the “validation
cohort” (n = 24) carrying the same molecular features (i.e. without mutations in NPM1,
CEBPA and FLT3–ITD) than the “discovery cohort”. Among them, 75% carried mutations in
ASXL1,DNMT3A and/or RUNX1. Other genes such as DNAH9, IDH2,WT1,DNAH8, NRAS
or TET2were also recurrently mutated within this set of patients (Fig 2A). In addition,
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although DNMT3Amutations tend to appear as isolated alterations, ASXL1 and RUNX1muta-
tions mainly co-occur among them and with mutations in other genes (Fig 2B). In both cases,
given the nature of these genes, the epigenetic regulation might be compromised. Moreover,
we extended our analysis to the mutations described in AML patients from the TCGA cohort
with the same molecular features (n = 20). Within TCGA patients, the most frequently
mutated genes were DNMT3A, RUNX1, IDH2, TET2, and NRAS. Taking into account both
sets of patients, we obtained an input of 44 samples with normal karyotype lacking mutations
in NPM1, CEBPA, and FLT3-ITD, who harbor mutations in: DNMT3A (32%), RUNX1 (28%),
ASXL1 (23%), IDH2 (21%), NRAS (17%), and TET2 (17%) genes.
Candidate gene prioritization
Focusing on the deleterious variants found in our AML patients, a gene prioritization analysis
was performed in order to define an in silicomodel based on the physical interaction, regulation,
Fig 1. Distribution of selected mutations along the different affected genes of the validation cohort. A) Number of mutated samples by gene according to the
described mutation filtering protocol. Only recurrent genes were included. B) Co-occurrence of all somatic mutations.
https://doi.org/10.1371/journal.pone.0202926.g001
Fig 2. Distribution of selected mutations along the different affected genes among validation cohort with same molecular features than the discovery cohort. A)
Number of mutated samples by gene according to the described mutation filtering protocol. Only recurrent genes were included. B) Co-occurrence of all somatic
mutations.
https://doi.org/10.1371/journal.pone.0202926.g002
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functionality and cell pathway alterations caused by each mutation. The analysis included the
interactome of the 28 candidate genes selected by harboring recurrent mutations and displaying
SIFT values in the range of the deleteriousness, with significant intrinsic mutation rates (NPM1,
DNMT3A,NRAS, PTPN11, IDH2, KRAS,WT1, IDH1, RUNX1, U2AF1,CEBPA, TP53,CHD4,
PCDHA6, GATA2, ASXL1,DLG1, BCOR, PKD1L2, SIPA1L2,MAGI1, FAM70B, FCGBP,TET2,
DNAH9, TEKT4, FLT3). We identified a network in which 19 out of the 28 genes were found to
be significantly more connected that the random expectation (P = 0.02) (Fig 3). Moreover, 13
genes (NPM1,DNMT3A,NRAS, PTPN11, IDH2,KRAS,WT1, IDH1, RUNX1, U2AF1,CEBPA,
TP53,CHD4) also displayed an accumulation of mutations significantly higher that the corre-
sponding healthy controls taken from the 1000 genomes repository (P0.01) [17]. Focusing on
these genes, we found an average of 2 altered genes by patient. Although not always the same
pathway was altered, the DNA methylation pathway prevailed above the others. Indeed, more
than half of the patients had alterations in the genes involved in this pathway. Moreover, the co-
occurrence of mutations in genes involved in less frequent pathways (i.e. signalling activation,
Fig 3. Network-based analysis (SNOW; Babelomics) applied to 28 selected genes. The network was complemented with the co-
occurrence relationships, in order to summarize the two kind of significant results. Significant network-based analysis genes are
coloured depending on their biological role and circle shaped. Intermediate genes were painted in white and square shaped. While grey
edges represent protein-protein interaction, relationships, broad orange dashed lines describe significant co-occurrences.
https://doi.org/10.1371/journal.pone.0202926.g003
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chromatin modification, transcription factors and cohesine complex) may trigger the leukemo-
genesis (Fig 4).
In addition, according to the in silicomodel, we were able to classify patients in 3 different
sets: patients with NK and/or well- known gene mutations that is, NPM1, CEBPA, and/or
FLT3–ITD (Group 1, n = 56); patients with NK and lacking mutations in NPM1, CEBPA, and
FLT3–ITD (Group 2, n = 22); and IR patients with cytogenetic abnormalities and/or known
molecular features, NPM1, CEBPA, and/or FLT3–ITD (Group 3, n = 22). According to these,
we found 3 different pathways rather similar between them. Comparing all the pathways, we
defined a single in silicomodel including the alterations detected in our sets of patients (Fig 5).
Focusing on group 1 and 2, we established a set of seed-genes that might be potentially
involved in leukemogenesis due to not being present in patients harboring cytogenetic abnor-
malities (Group 3), such as NSD1 (12%), PLCE1 (9%), NFATC2 (5%), EPHB1 (5%), ERG (4%),
NEDD9 (3%) and PIK3R1 (3%). Pathways affected by the presence of these mutations might
have a similar effect in the cell than IR-cytogenetic alterations.
Clinical correlations
Variables included in the regression analyses were age, gender, WBC count, platelet count,
percentage of bone marrow and peripheral blood blasts, cytogenetic risk group, MRC code,
ECOG, mutational status of NPM1 (exon 12), FLT3, CEBPA, and all those genes analyzed by
NGS. The follow-up of the patients was updated on December 2017, and all follow-up data
were censored at that time point. The median follow-up of surviving patients was 52 months
(range, 26 to 164).
No significant correlation was found between the mutations detected and the clinical or
biological features studied. In addition, our results did not show statistically significant pattern
of cooperating mutations in the studied group of genes. However, results from the elastic net
cox regression regarding overall survival, displayed a complex pattern of associations between
the different mutations and risk of death, with 26 different variables and age interacting. Haz-
ard ratios are presented in Table 1 and partial dependence plots for the different variables are
depicted in S1 Fig. With reference to event-free survival values, a higher risk of adverse event
was associated to mutations in DNAH8, TET2, RUNX1, andWT1; whilst a lower risk of
adverse event was correlated to the presence of mutations in KDM6A. Hazard ratios are pre-
sented in Table 2. To facilitate the interpretation of these results, partial dependence plots for
the different variables are provided in S2 Fig.
Discussion
This study shows a comprehensive analysis of AML, combining WES with the assessment of
somatic mutations by a custom next-generation sequencing panel of targeted genes with net-
work enrichment analysis. In the “discovery cohort”, we identified and validated 64 deleterious
Fig 4. Distribution of mutations according to their functional category among the validation cohort.
https://doi.org/10.1371/journal.pone.0202926.g004
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somatic variants in 55 genes that were further targeted sequencing in the “validation cohort”
of patients along with 32 extra genes previously reported to play a significant role in AML
pathogenesis [10]. After bioinformatic filtering of variants, we identified likely deleterious
mutations in 73 genes, where 35 were previously reported as recurrent mutated in AML [10,
11]. Network enrichment analysis identified 13 recurrently mutated genes involved in
AML-IR pathogenesis. Among them, we defined a single in silicomodel and established a set
of seed-genes that may trigger leukemogenesis.
To identify leukemia-specific somatic alterations that could cooperate in the development
and progression of leukemia, WES analysis was performed in 7 tumor-normal matched sam-
ples. As a normal paired sample, we examined DNA from saliva or from bone marrow at com-
plete remission of each single case (defined according to the recommendations of Cheson
et al.). To prevent false-positive calls in WES, all stringent filtered variants were resequenced
by means of target NGS in paired samples of each patient using a different NGS platform.
Among them, 64 deleterious variants were confirmed to be true. Although our protocol took
into account several sequencing artifacts as strand bias and other measurable effects derived
from poorly mapped reads, some of the not validated mutations could be false positives inher-
ent in the technology used. Furthermore, the issue to confidently identifying indels or the pres-
ence of low frequency alleles could explain some false negative calls at the validation
resequencing. As a whole, these technical limitations might imply an underestimation of can-
didate mutated genes in the “discovery cohort”.
Fig 5. Network-based analysis (SNOW; Babelomics) applied to 28 selected genes. The network was complemented with the co-occurrence relationships, in order to
summarize the two kind of significant results. Significant network-based analysis genes are coloured depending their categorical group: patients with NK and/or well-
known gene mutations (Group 1, red), patients with NK and without mutations inNPM1, CEBPA and FLT3–ITD (Group 2, green) and IR patients with cytogenetic
abnormalities and/or known molecular features (Group 3, blue). Grey edges represent protein-protein interaction, relationships, broad orange dashed lines describe
significant co-occurrences.
https://doi.org/10.1371/journal.pone.0202926.g005
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In a first step, we identified 55 candidate genes, where 26 were previously reported as
mutated in AML patients in previous studies [10]. The identification of previously reported
driver mutations validated the robustness of our approach. Then, we extended the analyses
through the examination of our candidate genes in an independent validation cohort of 100 de
novo AML-IR patients. For this propose, a custom panel of 87 genes was designed. Although
custom panels require a previous design stage and are optimized by the laboratory, their main
advantage is the flexibility they offer, since you can include the regions of your interest and
change this design over time (add or remove regions) depending on the needs of each pathol-
ogy. As no germline matched sample was available from each patient, we implemented a
Table 1. Coefficients and their corresponding Hazard Ratios for overall survival based on predictive factors in
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germinality test previously described by our group [14]. In order to filter out the majority of
germline variants, we compared the mutations found in our patients against the healthy
1000G cohort and other public variant population databases. Finally, we found a mean of 4.89
mutations per sample (range 0–10) affecting 73 different genes of which 35 genes were recur-
rently mutated in more than one patient. Recurrent hotspots in genes such as DNMT3A,
NRAS,KRAS and IDH1/2were also present in several samples. In our whole validation cohort,
the most frequent mutated genes were NPM1,DNMT3A, FLT3, TET2, and ASXL1. These
results agreed with those previously reported [10, 11]. When we focussed our analysis on those
patients from the validation cohort with same molecular features than the discovery cohort
(n = 24), we found somatic mutations with deleterious effect in 100% of patients, mainly in
ASXL1,DNMT3A and/or RUNX1. There were other mutated genes within this set of patients
such as DNAH9, IDH2,WT1,DNAH8, NRAS or TET2. However, we found that almost 25% of
the patients carried DNMT3Amutations as an only alteration whilst 13% presented ASXL1
and RUNX1 in a simultaneous manner. Although this association was established evaluating a
subset of 24 patients, such observations might suggest that the alterations harboured by this set
of patients could derive in an aberrant epigenetics regulation. In line with recent reports,
highlighting the complex nature of genomic aberrations in leukemia [4, 6, 7], probably the
mechanisms that trigger the leukemogenic process could have a common consequence. Func-
tional validation studies will be required to assess the importance of these mutations for AML
pathogenesis when well established mutations are not present.
Likewise, exploratory in silico approaches were used to provide a reliable approach to prior-
itize genes that would undergo additional analysis. Candidate genes were selected according to
the recurrence of mutations and their SIFT values in the range of the deleteriousness as it has
been previously reported [14]. Network analysis resulted in a significantly connected subnet-
work in which 19 of 28 genes were significantly more connected that the random expectation.
Amidst, 13 genes (NPM1,DNMT3A,NRAS, PTPN11, IDH2, KRAS,WT1, IDH1, RUNX1,
U2AF1,CEBPA, TP53,CHD4) also displayed an accumulation of mutations significantly
higher that the corresponding healthy controls taken from the 1000 genomes repository. This
result strongly suggests that all these genes are close in the interactome, as frequently occurs
with genes of the same disease [18,19]. The epigenetic regulation is affected in these patients
directly or through the interactome neighborhood by specific combinations of mutations that
contribute to the arising and maintenance of AML. When we classified patients in 3 different
sets according to their harbored mutations [Group 1, (n = 56), Group 2, (n = 22), Group 3,
(n = 22)] we established a set of seed-genes that could be potentially involved in leukemogene-
sis due to not being present in patients with cytogenetic abnormalities (ERG,NSD1, PLCE1,
NFATC2, NEDD9, PIK3R1, and EPHB1). The consequence of these mutations might have a
similar effect in the cell than those presents in IR-cytogenetic alterations. As a member of the
ETS (erythroblast transformation-specific) family of transcription factors, ERG (ETS-related
gene) regulates transcription probably by modifying the structure of the chromatin. In leuke-
mia, ERG targets transcription factors such as GATA2, which is an important regulator of
hematopoietic stem cell and megakaryocyte development and, RUNX1, which is involved in
the development of normal hematopoiesis. Functional analyses conducted in mice and human
CD34 normal and leukemic cells have demonstrated the role of ERG in the induction of early
myeloid progenitors in leukemia stem cell through the activation of RAS pathway and Pim1
[20–24]. Several studies have established the prognosis impact of ERG expression on adult
patients with AML, improving the molecular risk stratification of NK-AML [22, 25–29].
Although mutations in ERG have not been reported in previous AML studies, 222 different
mutations affecting 211 patients in other cancers (n = 22) such as breast, brain or soft tissue
have been described. NSD proteins are epigenetic regulators that methylate lysine side chains
The modular network of Acute Myeloid Leukemia
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affecting chromatin organization. This protein is encoded by NSD1 gene and plays a pivotal
role in childhood acute myeloid leukemia (AML). This gene has been described in a cryptic
rearrangement with NUP98 in 15–20% of children with NK-AML. However, the oncogenic
fusion transcript is rarely found in adults (~2%) [30–32]. In previous results, mutations in this
histone methyltransferase has been detected at low frequency in AML (~3%) and its impact on
the outcome of AML patients still remains unclear [10, 33, 34]. PLCE1 belongs to a phospholi-
pase family that controls gene expression, cell growth and differentiation. A total of 665 differ-
ent mutations have been reported in several types of cancer. In particular, mutations in PLCE1
have been described in ~3% of patients with AML [10]. NFATC2 is a member of a protein fam-
ily that acts as a transcription factor in immune response participating in the maturation of
peripheral lymphocytes [35–38]. Mutations (n = 326) in this gene have also been reported in
293 patients from 19 different types of cancer [10]. Particularly, several studies performed in
ALL patients (n = 3308) have associated NFATC2 mutations with a poor outcome by increas-
ing the risk of asparaginase hypersensitivity [39]. NEDD9 regulates tyrosine-kinase-based sig-
naling complexes involved in multiple actions such as cell adhesion, migration and apoptosis,
affecting cancer metastasis [40–43]. In addition, this gen has been related to BCR receptor in
B- and T-cell and the inhibition of migration and dissemination of neoplastic myeloid cells
[44–47]. Recently, Pallarès et al. have studied two independent cohorts of AML patients
(n = 279) and established NEDD9 gene expression as a favorable prognosis factor in IR-AML
patients subgroup [48]. Moreover, mutations in this gene have been associated with drug resis-
tance in several solid tumors [10]. Gain-of-function mutations in PIK3R1 have been associated
with an oncogenic activation of PIK signaling pathway which plays an important role in the
regulation of FGFR family, PDGFRA,PDGFRB and KIT genes, among others [49, 50]. Previous
reports have described mutations in PIK3R1 in leukemia (6.4%), establishing PIK3R1 as an
actionable gen in AML [51, 52]. Finally, human and murine myeloid assays have shown a
reduction of BCR-ABL transformation by inhibiting PI3K/AKT pathway [53–56]. Finally,
EPHB1 is a receptor tyrosine kinase involved in normal hematopoietic development and in
leukemogenesis [57]. Mutations causing a loss-of-function in this gene have been associated with
an aggressive cancer phenotype [58, 59]. In AML, EPHB1 has been defined as a tumor suppressor
that regulates DNA damage response system; therefore, mutations affecting this gene have been
correlated with poor overall survival [60, 61]. Moreover, mutations disturbing EPHB1methylation
have been related with ALL pathogenesis [62]. Since mutations in these seed genes are very rare in
previously published AML cohorts [10], they could trigger leukemogenesis only in this subset of
AML patients which lack cytogenetic alterations and/or well-known molecular features that is,
wild-typeNPM1,CEBPA, and FLT3–ITD. For these reason, the impairment of a specific alteration
could not be as essential as the interaction of several mutated genes belonging to functionally
related categories in the development of AML. Further analysis will focus on the characterization
larger and independent cohorts of patients with NK-AML to establish the frequency and their
impact on the leukemogenesis. In addition, to improve our knowledge about their interactions, in
vitro assays will be performed by gene editing technologies. With this purpose, observed muta-
tions will be introduced in cell cultures to transform these results into data of clinical relevance
that will be virtually used in the prognostic and therapeutic decision process.
Three major limitations to our study are the relative small sample size, their selection bias
and normal-matched samples. We have analyzed an initial cohort of 7 patients by WES and 100
patients by a targeted gene-panel using NGS. As a consequence, to perform a study of a specific
group of patients, there were not randomly included in our study. For this reason, it has been
difficult to set up a significant independent association for any gene mutation using univariate
or multivariate analysis. However, by conducting an elastic net cox regression, we found a com-
plex pattern of associations between the different mutations and risk of death, consistent with
The modular network of Acute Myeloid Leukemia
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previous reports [10–12]. In this regard, we used regularized regression methods in our statisti-
cal analyses to reduce over-fitting in small samples and deal appropriately with analyses were
the number of variables is high relative to the number of observations [63, 64]. Therefore, more
solid evidence based on larger series with long-term follow-up is needed to correlate our results
with other clinical data and to clarify the prognostic impact of each mutation. In addition, the
use of bone marrow sample from complete remission as “normal” matched control could have
led us to discard somatic variants persistent at complete remission. The same for the saliva sam-
ple, which could be contaminated with leucocytes. Therefore, we could underestimate candidate
mutated genes in our discovery cohort. However, we were interested in those mutations that
trigger leukemogenesis, which should not be present when patients achieve complete remission.
In summary, this report describes a complete analysis of AML patients with NK combining
WES, targeted NGS and network enrichment approaches. As a result, in 100 AML patients we
have described mutations in 73 genes, 35 of them recurrently mutated. Additionally, we have
defined a functional module in the interactome of AML pointed 13 recurrent mutated genes
significantly involved in the pathogenesis of AML. After classify patients according to their
mutations, we defined a single in silicomodel and established a set of seed-genes that may trig-
ger leukemogenesis. These results led us to hypothesize that the perturbation caused in biologi-
cal key functions as a consequence of gene mutations might be at least as important as the
combination of mutations harbored in each patient. Finally, it is clear that the understanding
of the events occurred at the clonal hematopoiesis in this disease is still limited and the future
potential of discovery of new pathways interactions is high.
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